What's new?
04/04/2018

• Sofinnova Crossover 1 est le plus grand fonds crossover dédié à la santé en Europe.
• Avec ce nouveau fonds, Sofinnova Partners poursuit activement sa stratégie visant à élargir sa plateforme d’investissements en sciences de la vie sur l’ensemble de la chaîne de valeur, de l’amorçage aux sociétés de croissance.
• Bpifrance* et CNP Assurances sont co-sponsors du fonds.

Paris, France – 4 avril 2018 — Sofinnova Partners, un leader du capital-risque en Europe spécialisé dans les sciences de la vie, annonce le lancement de son premier fonds crossover dédié à la santé en Europe, d’un montant de 275 millions d’euros (340 millions de dollars), au-delà de l’objectif du premier closing à 250 millions d’euros. Avec ce nouveau fonds, Sofinnova Partners franchit une étape supplémentaire dans le déploiement de son projet de croissance visant à étendre son champ d’intervention dans les différents segments de l’investissement dans les sciences de la vie, grâce à des équipes dédiées.

Dans la continuité de la stratégie appliquée avec succès depuis plusieurs décennies avec ses fonds Capital intervenant en early-stage, Sofinnova Crossover I investira dans la biopharmacie et l’instrumentation médicale. Il ciblera en priorité des technologies de rupture permettant des innovations thérapeutiques portées par des équipes managériales expérimentées. Sofinnova Partners investira comme chef de fil ou investisseur de référence dans une quinzaine d’entreprises privées ou cotées. Environ 80% du fonds seront investis en Europe, et les 20% restants ailleurs, principalement en Amérique du Nord. Une équipe de quatre associés très expérimentés investira le fonds, en s’appuyant sur l’expérience élargie de Sofinnova Partners, son track record et son organisation. Ce nouveau fonds a su attirer la confiance d’investisseurs internationaux de premier plan, notamment des fonds souverains, compagnies d’assurance, corporate, et family offices. La majorité des fonds levés viennent d’Europe, en particulier de France, d’Italie, du Danemark, d’Irlande et de Suisse, mais aussi d’Asie avec des investisseurs originaires de Chine et de Singapour. En plus de BPIfrance* et de CNP Assurances, une société pharmaceutique chinoise de premier plan, le fonds public d’investissement danois, et des family offices tels que Fidim et KCK représentant de grandes familles industrielles d’Europe et d’Asie figurent parmi les investisseurs du nouveau fonds.

Antoine Papiernik, Président de Sofinnova Partners, déclare : “Avec le lancement de l’activité crossover, Sofinnova Partners construit sur son track record unique en early-stage. Beaucoup des entreprises que nous avons financées dès leur démarrage sont devenues au cours des années de grandes entreprises, certaines valorisées plusieurs milliards d’euros ; nous avons ainsi acquis une expérience unique sur la façon de les accompagner au stade d’après. Ce fonds complète notre plateforme d’investissement dans les sciences de la vie, nous permettant d’être actifs tout au long de la chaîne de valeur depuis l’investissement d’amorçage jusqu’aux phases plus avancées.”

Jacques Theurillat, Partner dans l’équipe crossover de Sofinnova Partners, poursuit : “Le marché européen de la santé est devenu mature avec des centaines d’entreprises privées et cotées à la recherche de fonds pour financer leur croissance, et Sofinnova Partners, avec son image de marque, son track record, et son expérience, est idéalement positionnée pour identifier les meilleures opportunités en Europe et accompagner leur transformation en leaders internationaux.”

Sur ce fonds Sofinnova Crossover I, Triago a agi en tant qu’agent de placement et Clifford Chance Europe LLP en tant que conseil juridique.

*Bpifrance intervient pour son compte propre et pour le compte du SGPI dans le cadre du Programme d’investissements d’Avenir (PIA)

Contact presse pour SOFINNOVA PARTNERS
Anne REIN Tel: +33 (0)6 03 35 92 05 @: anne.rein@strategiesimage.com

A propos de Sofinnova Partners
Sofinnova Partners est un des leaders du capital risque en Europe spécialisé dans les sciences de la vie. Basée à Paris, l’équipe est composée de professionnels issus d’Europe, des Etats Unis et de Chine. La société investit dans les technologies de changement de paradigme aux côtés d’entrepreneurs visionnaires. Sofinnova Partners intervient en priorité dans les start up et spin-off d’entreprises en tant qu’investisseur fondateur et chef de file. Depuis 45 ans, la société a accompagné plus de 500 entreprises à travers le monde devenues des leaders sur leur marché. Sofinnova Partners gère aujourd’hui 1,9 milliard d’euros.

23/10/2014
dbv_nasdaq
24/09/2014

LEIDEN, The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR) announced today the closing of its initial public offering of 8,625,000 ordinary shares at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,125,000 additional ordinary shares. The aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $102 million. The company’s ordinary shares were approved for listing on the NASDAQ Global Market and began trading under the symbol « PRQR » on September 18, 2014.
Leerink Partners and Deutsche Bank Securities acted as joint book-running managers for the offering. JMP Securities acted as lead manager, and H.C. Wainwright & Co., LLC acted as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at Syndicate@Leerink.com, or by phone at 800-808-7525 ext. 6142; or from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by email at prospectus.cpdg@db.com, or by phone at (800) 503-4611.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ProQR
We are an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis. Utilizing our unique, proprietary RNA repair technologies, we believe we will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation. We believe that this is a unique approach that offers advantages compared with small molecule, gene therapy and other therapeutic strategies.

ProQR:
Daniel de Boer
Chief Executive Officer
T: +31 85 489 49 32
info@proqr-tx.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
T: +49 172 861 8540
gschweitzer@macbiocom.com

Source: ProQR Therapeutics N.V.

19/09/2014

ProQR Therapeutics est une société de biotechnologie spécialisée dans le traitement des maladies génétiques sévères avec un focus initial sur la mucoviscidose

Paris, le 19 septembre 2014. Sofinnova Partners, société de capital-risque dans les sciences de la vie basée à Paris, annonce le succès de l’introduction en bourse de ProQR Therapeutics sur le NASDAQ Global Market de New York. Sofinnova Partners était le seul investisseur institutionnel au capital de cette société spécialisée dans le traitement de la mucoviscidose lors son premier tour d’amorçage en 2013, et était l’investisseur leader de la série A clôturée en avril 2014 et ayant réuni 42M€ auprès de prestigieux investisseurs américains.
Basée à Leiden (Pays-Bas), ProQR Therapeutics est une société de biotechnologie qui développe des thérapies reposant sur l’ARN pour le traitement de maladies génétiques sévères avec un focus initial sur la mucoviscidose. La plateforme technologique propriétaire unique que développe ProQR est destinée à traiter la déficience d’une protéine lorsqu’elle est causée par un certain type de mutation génétique. Le fondateur et PDG de ProQR Therapeutics, Daniel De Boer, a réuni autour de lui une équipe de management très expérimentée et s’est entouré de co-fondateurs prestigieux parmi lesquels Dinko Valerio, scientifique et entrepreneur de renom qui a précédemment créée la biotech Crucell, rachetée par Johnson & Johnson, et Henri Termeer, ancien Chairman et CEO de la société Genzyme, depuis vendue à Sanofi.
Antoine Papiernik, partenaire-associé chez Sofinnova Partners et membre du Conseil d’administration de ProQR Therapeutics, déclare : « Nous sommes très heureux d’accompagner depuis son tour d’amorçage cette équipe performante. ProQR Therapeutics a une approche extrêmement innovante, dans un domaine où les besoins thérapeutiques des patients atteints de maladies génétiques, et en particulier de mucoviscidose, sont encore largement insatisfaits ».
L’introduction en bourse a porté sur 7,5 millions de titres dont le prix a été fixé à $13. La cotation sur le NASDAQ Global Market a démarré le 18 septembre 2014 sous le symbole « PRQR ». Se référer au communiqué de la société (en PJ) pour de amples informations sur l’opération.

A propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris. Depuis 40 ans, la société a financé près de 500 sociétés – start-up, spin-off et opérations de retournement. Elle a accompagné les plus grands entrepreneurs européens dans le domaine des sciences de la vie. Avec 1,3 milliard d’euros sous gestion, l’équipe de Sofinnova Partners, reconnue pour sa capacité à aider et à soutenir les entreprises de son portefeuille de la création à la sortie, a permis l’émergence de leaders sur leurs marchés. Tournée vers l’international, la société investit à travers l’Europe à partir de son bureau parisien, et sa société soeur Sofinnova Ventures se situe à Palo Alto.

19/09/2014

LEIDEN, Netherlands, Sept. 18, 2014 – ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share. In addition, ProQR has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares from ProQR at the public offering price, less underwriting discounts and commissions. After deducting the underwriting discounts and commissions and other estimated offering expenses payable by ProQR, the net proceeds of the initial public offering are expected to be approximately $88.4 million. The offering is expected to close on or about September 23, 2014, subject to customary closing conditions. ProQR’s ordinary shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the symbol « PRQR » on September 18, 2014.
Leerink Partners and Deutsche Bank Securities are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager, and H.C. Wainwright & Co., LLC is acting as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2014. The offering will be made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at Syndicate@Leerink.com, or by phone at 800-808-7525 ext. 6142; or from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by email at prospectus.cpdg@db.com, or by phone at (800) 503-4611.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ProQR
We are an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis. Utilizing our unique, proprietary RNA repair technologies, we believe we will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation. We believe that this is a unique approach that offers advantages compared with small molecule, gene therapy and other therapeutic strategies.

CONTACT: ProQR:
Daniel de Boer
Chief Executive Officer
T: +31 85 489 49 32
info@proqr-tx.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
T: +49 172 861 8540
gschweitzer@macbiocom.com

Source: ProQR Therapeutics BV

17/09/2014

Interim analysis shows annualized three month height velocity is comparable to the active comparator, Genotropin®, given at an equivalent cumulative weekly dose

Continue Reading…

10/09/2014

Geneva, Switzerland, 10 September 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women’s reproductive medicine, announced today the appointment of Ben T.G. Tan as Vice President Commercial & Business Development.
Ben brings to ObsEva over 25 years of business development, licensing and strategic marketing experience in clinical-stage biotechnology and pharmaceutical companies.
“I am delighted that Ben is joining ObsEva, as his experience will be invaluable for further expanding and optimising ObsEva’s product pipeline to address unmet medical needs and to create the highest value for all our stakeholders ” stated Ernest Loumaye, CEO and Co-Founder of ObsEva.
Ben joins ObsEva from Evolva SA, where he successfully divested its lead Phase 2 asset as part of Evolva’s strategic shift away from pharmaceutical development and towards ingredients for health, wellness and nutrition. As Head of Business Development & Licensing at Speedel AG (2001-2008), Ben in-licensed preclinical and clinical assets and contributed to Speedel’s IPO in September 2005. After Speedel’s acquisition by Novartis Pharma AG for CHF 1 billion in 2008, he joined Novartis as Global Program Strategic Marketing Director and led the commercialisation activities for an antiplatelet drug. Prior to Speedel, Ben was Head of Global Licensing at Organon NV, a leader in Women’s Health Care.
Ben began his pharmaceutical industry career at Roche Netherlands as a sales representative for hospital products and progressed to become Head of Medical Marketing, in which role he successfully launched Neupogen (filgrastim) in a co-promotion with Amgen Europe, before moving to Roche HQ in Basel as Global Business Leader for various Phase 3 assets in co-development with Sigma-Tau and Genentech.
Ben holds an MS (cum laude) in Medical Biology from the Vrije Universiteit Amsterdam.

About ObsEva
ObsEva SA is a Swiss-based, specialty biopharmaceutical company dedicated to the development and
commercialisation of innovative drugs for women’s reproductive medicine. ObsEva was founded in
November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist
in female reproductive medicine with 20 years of experience in the biopharmaceutical industry.
Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical
company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and
pharmaceutical chemistry with more than 30 years of experience in various positions in the
biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was
responsible for the preterm labor program at Serono before the acquisition of the company by Merck
KGaA.
ObsEva’s founding assets are innovative products at early stages of clinical development addressing
preterm labor and infertility treatment as well as additional indications in reproductive medicine.

For more information, please visit www.obseva.com.
For further information, please contact ObsEva CEO Office:
Delphine Renaud
Tel: +41 22 552 1550
Email: delphine.renaud@obseva.ch

09/09/2014

Patent Underpins FX006 Formulation Technology and Provides Intellectual Property Protection Into 2031

BURLINGTON, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent (No. 8828440), entitled « Corticosteroids for the Treatment of Joint Pain, » which provides coverage for FX006, the company’s lead clinical product candidate. FX006 is a novel, non-opioid, sustained-release, intra-articular (IA) formulation of triamcinolone acetonide (TCA). The patent describes and claims an injectable formulation comprised of controlled or sustained-release microparticles that contain TCA in a poly(lactic-co-glycolic) acid co-polymer (PLGA) matrix.
« The issuance of this patent marks an important milestone for Flexion as it directly protects our lead product, FX006, for a prolonged period of time and provides a critical foundation for its eventual commercialization, » said Michael Clayman, M.D., President and CEO. « Based on the available clinical data to date, we are enthusiastic about the prospect of FX006 playing an important role in the treatment of patients with osteoarthritis (OA) of the knee. This patent, together with last week’s announcement on the planned start of our pivotal Phase 3 clinical trial for FX006 a year ahead of schedule, brings us closer to realizing the potential of this novel therapy. »
FX006 is designed to provide prolonged pain relief for the treatment of OA of the knee, while potentially avoiding untoward systemic effects associated with immediate-release steroids. Last year Flexion announced the results of a Phase 2b OA dose-ranging trial that demonstrated that FX006 provided superior pain relief compared to the standard of care IA immediate-release steroid. Flexion also recently announced positive topline clinical trial results from a Phase 2a synovial fluid pharmacokinetic (PK) trial of FX006, which demonstrated, for the first time, that a single IA injection of FX006 can provide therapeutic concentrations of FX006 in joint fluid for at least 12 weeks. A pivotal Phase 2b confirmatory clinical trial for FX006 is currently enrolling patients and topline data are expected in the first half of 2015. Based on a recent meeting with the U.S. Food and Drug Administration (FDA) to review the clinical development program for FX006, Flexion earlier this month announced plans to accelerate the initiation of a pivotal Phase 3 clinical trial for FX006 to late 2014 and expects to complete the trial by the second half of 2015. The Phase 3 trial will be an international, multi-center, randomized, blinded, single-dose study in 462 patients with OA of the knee. It will have three separate arms that include a 40 mg dose of FX006, placebo, and a 40 mg dose of TCA. The primary objective of the trial will be to provide the second pivotal efficacy dataset against placebo for an NDA submission. In addition, the trial will provide a key comparative dataset against the current standard of care, immediate-release TCA, and could potentially support a commercial advantage in the launch of the drug.

About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company’s lead program, FX006, is an intra-articular sustained-release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.
Forward-Looking Statements

Statements in this press release regarding matters that are not historical facts, including statements relating to the future of Flexion, its ongoing development of its product candidates, the potential duration and impact of patent protection for FX006, anticipated clinical and other milestones (including the timing of such milestones), and potential role of FX006 in the treatment of patients with OA of the knee are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks associated with the process of discovering, developing and obtaining regulatory approval for drugs that are safe and effective for use as human therapeutics, whether the company’s patents will be held valid and enforceable, the fact that Flexion relies on third parties to manufacture and conduct the clinical trials of its product candidates, which could delay or limit their future development or regulatory approval, the possibility that future trial results may not be consistent with past results, the fact that Flexion will require additional capital, including prior to completing Phase 3 development of, filing for regulatory approval for, or commercializing, FX006 or any of its other product candidates and may be unable to obtain such additional capital in sufficient amounts or on terms acceptable to it, and other risks and uncertainties described in Flexion’s filings with the Securities and Exchange Commission (SEC), including under the heading « Risk Factors » in Flexion’s Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings with the SEC. You are encouraged to read Flexion’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and Flexion undertakes no obligation to update or revise any of the statements.

CONTACT: Media Contact
Jamie Lacey-Moreira
PressComm PR, LLC
T: 410-299-3310
jamielacey@presscommpr.com

Corporate Contact
Lisa Davidson, MBA
Vice President, Finance and Administration
Flexion Therapeutics, Inc.
T: 781-305-7765
ldavidson@flexiontherapeutics.com

Source: Flexion Therapeutics, Inc.

03/09/2014

Paris. September 2. 2014. Sofinnova Partners, a Paris-based life science venture capital firm, reinforces its investment team with the appointment of Henrijette Richter as Partner.

Henrijette has over ten years of investing experience in venture capital. For the past seven years she was an Investment Director at Novo Seeds, part of Novo A/S (Denmark), which she co-established. Henrijette holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen, and did her postdoctoral fellowship at MIT Center for Cancer Research, Cambridge. She has invested and serves on the Board of several biotech companies such as Affinicon, Orphazyme, EpiTherapeutics, Avilex Pharma, and Lysogene.

Henrijette Richter says: “I am delighted to join Sofinnova Partners’ experienced and talented team. We have worked together in the past through co-investments, and share a common vision, to back strong entrepreneurs and help them successfully bring ground-breaking innovations to market”.
Denis Lucquin, Managing Partner at Sofinnova Partners says: “Henrijette is a great addition to our team and we are extremely pleased to welcome her. Henrijette has a solid investment experience in our field, a remarkable scientific background, and a very strong network, in particular in Scandinavia, an important territory for our strategy”.

About Sofinnova Partners
Sofinnova Partners is an independent venture capital firm based in Paris, France. For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside key entrepreneurs in the Life Sciences industry around the globe. With over €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit.

11/08/2014

ZUG, Switzerland, Aug. 11, 2014 — Auris Medical Holding AG announced today the closing of its previously announced initial public offering of 9,400,000 of its ordinary shares at an initial public offering price of USD 6.00 per ordinary share. In addition, Auris Medical granted the underwriters a 30-day option from August 6, 2014 to purchase up to an additional 1,410,000 ordinary shares at the public offering price, less underwriting discounts. Auris’ ordinary shares were approved for listing oh the NASDAQ Global Select Market and began trading under the symbol « EARS » on August 6, 2014.

Jefferies LLC and Leerink Partners LLC acted as joint book-running managers for the offering. JMP Securities LLC and Needham & Company, LLC acted as co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (« SEC ») on August 5, 2014. The offering was made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by emailing Prospectus_Department@Jefferies.com, or by calling (877) 547-6340Call: (877) 547-6340 or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by email at syndicate@leerink.com, or by calling (800) 808-7525Call: (800) 808-7525.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.

Contact:
Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94Call: +41 41 729 71 94, ear@aurismedical.com

23/07/2014

Genève, Suisse, 23 juillet 2014 – ObsEva, une société biopharmaceutique suisse dédiée au développement de médicaments innovants en médecine de la reproduction, et portant son intérêt principal sur les traitements de la menace d’accouchement prématuré et de l’infertilité, a annoncé aujourd’hui l’obtention du statut JEDI attribué par le Canton de Genève et du statut européen de SME octroyé par l’Agence européenne des médicaments.
Le statut JEDI (“Jeune Entreprise Développant des Innovations“), a été créé en 2010 par le Grand Conseil de la République et du Canton de Genève. Ce statut démontre la reconnaissance de l’activité innovante de ObsEva au sein de la région genevoise et permet d’étendre son rayonnement à toute la Suisse. “Nous sommes fiers de pouvoir contribuer au développement économique du Canton de Genève qui offre et maintient un environnement très propice à l’essor des start-up dans le domaine des sciences de la vie. Le statut JEDI permettra de faciliter les échanges avec les autorités locales.” déclare Ernest Loumaye, Directeur Général et Co-Fondateur de ObsEva.
“Genève joue un rôle primordial dans le domaine de la santé. C’est une région de petite taille et attrayante où se concentrent des acteurs des sciences de la vie, des organisations internationales, des institutions de recherche et établissements universitaires, des entreprises start-up et de grandes multinationales. Nous nous réjouissons de pouvoir accueillir ObsEva comme nouvel acteur au sein de ce noyau dynamique.” ajoute Daniel Loeffler, Directeur du Service de la Promotion Economique de Genève.
ObsEva a également annoncé aujourd’hui que l’Agence européenne des médicaments (EMA) avait confirmé le statut européen de SME (Small and Medium Enterprise) de ObsEva. Le statut de SME visant à promouvoir l’innovation et le développement de nouveaux médicaments à usage humain et vétérinaire avait été adopté par la Commission Européenne le 15 décembre 2005, par le biais de dispositions spécifiques. Les mesures incitatives liées à ce statut comprennent notamment une aide administrative, une assistance pour les procédures mais aussi diverses réductions, exonérations ou reports de frais et cotisations.

A propos de ObsEva
ObsEva SA est une société biopharmaceutique Suisse dédiée au développement de nouvelles classes de médicaments en médecine de la reproduction. ObsEva a été fondée en novembre 2012 par Ernest Loumaye MD, PhD et André Chollet PhD. Ernest Loumaye est un spécialiste en médecine de la reproduction de la femme, disposant de 20 ans d’expérience dans l’industrie biopharmaceutique. Ernest Loumaye a été le co-fondateur et CEO de PregLem SA, société biopharmaceutique dont la réussite a conduit à son acquisition en 2010 par la société Gedeon Richter. André Chollet est un spécialiste en chimie médicale et pharmaceutique avec plus de 30 ans d’expérience dans l’industrie biopharmaceutique, dont Biogen, GSK et Merck Serono. André Chollet était responsable du programme pour le traitement de la menace d’accouchement prématuré chez Serono, avant le rachat de la société par Merck KGaA.
Le portefeuille de produits de ObsEva est constitué de produits innovants, à un stade de développement clinique précoce, destinés au traitement de la menace d’accouchement prématuré et de l’infertilité, ainsi que d’autres traitements en médecine de la reproduction.
Pour en savoir plus, consultez www.obseva.com.
Pour plus d’informations, veuillez contacter le bureau du Directeur Général de ObsEva :
Delphine Renaud
Tel: +41 22 552 1550
Email: delphine.renaud@obseva.ch